Karnataka: Syngene International has announced that the Company has received Establishment Inspection Report (EIR) from US ...

India's AI-driven biomanufacturing potential, challenges, and the need for balanced regulations and accountability in a ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...

LONDON, UK I June 12, 2025 I GSK plc (LSE/NYSE: GSK) announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...